LL-37 (Cathelicidin)
LL-37 is a natural human immune defense molecule (part of the cathelicidin family) that plays a key role in the body's first line of defense against infection. Research explores its antimicrobial, wound healing, and immune-regulating properties.
Verified sources for LL-37 (Cathelicidin)
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Overview of LL-37 (Cathelicidin)
Provides direct antimicrobial activity through membrane disruption while modulating immune responses and promoting wound healing.
Disrupts bacterial membranes through electrostatic interactions with phospholipids, and is active against gram-positive, gram-negative bacteria, fungi, and enveloped viruses.
May help prevent and disperse bacterial biofilms (proposed), relevant for chronic infection treatment.
Modulates inflammatory responses by affecting cytokine production, which can enhance or suppress inflammation depending on context.
Attracts monocytes, neutrophils, T cells, and mast cells to infection sites, acting as an alarmin in innate immune response.
May influence TLR signaling pathways (proposed), affecting downstream immune activation.
Promotes keratinocyte migration, angiogenesis, and epithelialization, enhancing wound closure.
Affects fibroblasts and endothelial cells (proposed), which may support tissue regeneration
Read Full LL-37 (Cathelicidin) Dosage Guide
Research-backed dosing protocols, timing, and administration details
Browse more in this category
Immune & Inflammation
Clinical Trials for Peptide Drugs Are Surging: Why the Pipeline Is Exploding in 2026
Peptide clinical trials have surged dramatically, with over 150 peptides now in active trials and 400+ in preclinical development. Here's why peptides are becoming the dominant drug class and what it means for the future of medicine.
RFK Jr. Says 14 Peptides Are Coming Back: Ban Reversal
HHS Secretary RFK Jr. told Joe Rogan that ~14 peptides banned by the FDA in 2023 will return to Category 1, restoring legal compounding access.